Ascendis Pharma (ASND) news
Recent news
Ascendis Pharma A/S: H.C. Wainwright cuts target price to $344 from $345
On August 31, 2026, H.C. Wainwright & Co. reiterated a 'Buy' rating for Ascendis Pharma A/S (ASND), maintaining adjusted price target of $344 , down from $345 previously. The firm cited continued confidence in the company’s growth potential and its innovative TransCon technology platform , which is…
AInvest Wire · 3h agoAscendis to pay Biomarin 20% royalty on US YuviaWell sales
AInvest Wire · 7h agoAscendis to dismiss all proceedings vs Biomarin
AInvest Wire · 7h agoAscendis to pay Biomarin 20% royalty on US yuviwel sales
AInvest Wire · 7h agoAscendis, Biomarin enter binding settlement term sheet
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Ascendis Pharma A/S have entered into binding terms to resolve all pending patent-related proceedings between the two companies, including litigation before the U.S. International Trade Commission (ITC) and in multiple jurisdictions across Europe,…
AInvest Wire · 7h agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.